Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: France,Greece,Netherlands,United States,Canada,United Kingdom,Australia,Belgium,Portugal,Germany - Promoter: nct
nct
Update Il y a 5 ans
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
This is an open-label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced HIV-1 patients. The primary objective is to determine the safety and pharmacokinetics of: TPV/RTV given with an optimized background regimen (OBR) and TPV/RTV given in combination with saquinavir, amprenavir, or Kaletra® and an optimized background regimen (OBR).
Country
Australia
,
Belgium
,
Canada
,
Denmark
,
France
,
Germany
,
Greece
,
Italy
,
Netherlands
,
Portugal
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1